AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Original) A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical composition into a human, and wherein the pharmaceutically acceptable carrier comprises deferoxamine in an amount effective to inhibit microbial growth in the pharmaceutical composition.

2. (Original) The pharmaceutical composition of claim 1, wherein the pharmaceutical agent is selected from the group consisting of anticancer agents, anesthetics, antimicrotubule agents, agents to treat cardiovascular disorders, antihypertensives, anti-inflammatory agents, anti-arthritic agents, antiasthmatics, analgesics, vasoactive agents, immunosuppressive agents, antifungal agents, antiarrhythmic agents, antibiotics, and hormones.

3. (Original) The pharmaceutical composition of claim 2, wherein the pharmaceutical agent is selected from the group consisting of paclitaxel, docetaxel, taxanes, camptothecin, propofol, amiodarone, cyclosporine, rapamycin, amphotericin, liothyronine, epothilones, colchicines, thyroid hormones, vasoactive intestinal peptide, corticosteroids, melatonin, tacrolimus, mycophenolic acids, and derivatives thereof.

4. (Original) The pharmaceutical composition of claim 3, wherein the pharmaceutical agent is propofol.

5. (Original) The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a liquid and comprises from about 0.1% to 25% by weight of albumin.

6. (Original) The pharmaceutical composition of claim 5, wherein the pharmaceutical composition comprises about 0.5% to about 5% by weight of albumin.

7. (Original) The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is dehydrated.

8. (Original) The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is lyophilized.

9. (Original) The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a mesylate salt of deferoxamine.

10. (Original) The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is a liquid and comprises from about 0.0001% to about 0.5% by weight of deferoxamine mesylate.

11. (Original) The pharmaceutical composition of claim 10, wherein the pharmaceutical composition comprises about 0.1% by weight of deferoxamine mesylate.

12. (Original) The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is dehydrated.

13. (Original) The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is lyophilized.

14. (Original) The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is an oil-in-water emulsion.

15. (Original) The pharmaceutical composition of claim 5, wherein the pharmaceutical agent is propofol.

16. (Original) The pharmaceutical composition of claim 10, wherein the pharmaceutical agent is propofol.

17. (Original) The pharmaceutical composition of claim 9, wherein the pharmaceutical agent is propofol, the propofol is present in an amount from about 0.1% to about 5% by weight, the albumin is present in an amount from about 0.1% to about 25% by weight, and the deferoxamine mesylate is present in an amount from about 0.0001% to about 0.5% by weight.

18. (Original) A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable

carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical composition into a human, and wherein the pharmaceutically acceptable carrier comprises deferoxamine in an amount effective to inhibit oxidation in the pharmaceutical composition.

Claims 19-76 (Cancelled)

77. (Original) A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical composition into a human, and wherein the ratio of albumin to pharmaceutical agent is about 18:1 or less.

78. (Original) The pharmaceutical composition of claim 77, wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 12:1 or less.

79. (Original) The pharmaceutical composition of claim 77, wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 9:1 or less.

80. (Original) A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to increase transport of the drug to the site of infirmity in a human, and wherein the ratio of albumin to pharmaceutical agent is about 18:1 or less.

81. (Original) The pharmaceutical composition of claim 80, wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 12:1 or less.

82. (Original) The pharmaceutical composition of claim 80, wherein the ratio of albumin to Currently Amended agent in the pharmaceutical composition is about 9:1 or less.

83. (Original) The pharmaceutical composition of claim 80, wherein the infirmity is selected from the group consisting of cancer, arthritis, and cardiovascular disease.

84. (Original) The pharmaceutical composition of claim 1, wherein the ratio of albumin to pharmaceutical agent is about 18:1 or less.

Claims 85-90 (Cancelled)

91. (Original) A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a protein in an amount effective to reduce one or more side effects of administration of the pharmaceutical composition into a human, and wherein the ratio of protein to pharmaceutical agent is about 18:1 or less.

92. (Original) The pharmaceutical composition of claim 91, wherein the ratio of protein to pharmaceutical agent in the pharmaceutical composition is about 12:1 or less.

93. (Original) The pharmaceutical composition of claim 91, wherein the ratio of protein to pharmaceutical agent in the pharmaceutical composition is about 9:1 or less.

94. (New) A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical composition into a human, and wherein the ratio of albumin to pharmaceutical agent is about 18:1 or less, wherein the pharmaceutical agent is selected from the group consisting of docetaxel, taxanes, camptothecin, propofol, amiodarone, cyclosporine, rapamycin, amphotericin, liothyronine, epothilones, colchicines, thyroid hormones, vasoactive intestinal peptide, corticosteroids, melatonin, tacrolimus, mycophenolic acids, and derivatives thereof.

95. (New) A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to increase transport of the drug to the site of infirmity in a human, and wherein the ratio of albumin to pharmaceutical agent is about 18:1 or less, wherein the pharmaceutical agent is selected from the group consisting of docetaxel, taxanes, camptothecin, propofol, amiodarone, cyclosporine, rapamycin, amphotericin, liothyronine, epothilones, colchicines, thyroid hormones, vasoactive intestinal peptide, corticosteroids, melatonin, tacrolimus, mycophenolic acids, and derivatives thereof.

96. (New) A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a protein in an amount effective to reduce one or more side effects of

administration of the pharmaceutical composition into a human, and wherein the ratio of protein to pharmaceutical agent is about 18:1 or less, wherein the pharmaceutical agent is selected from the group consisting of docetaxel, taxanes, camptothecin, propofol, amiodarone, cyclosporine, rapamycin, amphotericin, liothyronine, epothilones, colchicines, thyroid hormones, vasoactive intestinal peptide, corticosteroids, melatonin, tacrolimus, mycophenolic acids, and derivatives thereof.